Endothelial arginase: a new target in atherosclerosis.
Decreased endothelial nitric oxide (NO) bioavailability as it relates to endothelial dysfunction plays an important role in various cardiovascular disorders, including athero-sclerosis. Recent research has provided evidence that endothelial dysfunction in atherosclerosis is not primarily caused by decreased endothelial NO synthase (eNOS) gene expression, but rather deregulation of eNOS enzymatic activity, which contributes to the increased oxidative stress in atherosclerosis. Among other mechanisms, the substrate L-arginine is an important limiting factor for NO production. Emerging evidence demonstrates that L-arginine is not only converted to NO via eNOS, but also metabolized to urea and l-ornithine via arginase in endothelial cells. Hence, arginase competes with eNOS for the substrate L-arginine, resulting in deceased NO production. There are an increasing number of studies showing that enhanced arginase gene expression and/or activity contribute to endothelial dysfunction in various cardiovascular disorders, including atherosclerosis. Thus, endothelial arginase may represent a new therapeutic target in atherosclerosis.
Yang
Zhihong
Z
Vascular Biology, Department of Medicine, Division of Physiology, University of Fribourg, Rue du Musée 5, CH-1700 Fribourg, Switzerland. zhihong.yang@unifr.ch
Ming
Xiu-Fen
XF
D000818:Animals; D001119:Arginase / Q000378:metabolism*; D050197:Atherosclerosis / Q000201:enzymology*; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000201:enzymology*; D006801:Humans; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D018384:Oxidative Stress
D052250:Nitric Oxide Synthase Type III; D001119:Arginase